Variant rs9929218 Linked with Prognosis of Patients with CRC

Share this content:

the Cancer Therapy Advisor take:

Patients with stage 4 colorectal cancer (CRC) who have the variant rs9929218 at 16q22 (intron 2 of CDH1, encoding E-cadherin) are at an increased risk for worse survival and poor response to chemotherapy, according to an article published online in the journal Clinical Cancer Research.

Initially, the authors analyzed 20 single-nucleotide polymorphism (SNPs) associated with risk of CRC from 14 genome-wide loci and how they affected the prognosis of 2,083 patients with CRC.

Secondly, three SNPs were analyzed from an independent group of 5,552 patients with advanced stage CRC.

Results showed three variants in the training phase were associated with patient survival. However, only one variant (rs9929218) had a significant association in the validation phase.

Patients who were homozygous for the minor allele, especially those with stage 4 cancer (P=2.7 x 10-5), were observed to have worse survival (training phase HR, 1.43; 95% CI: 1.20, 1.71; P=5.8 × 10−5; validation phase; HR, 1.18; 95% CI: 1.01, 1.37; P=3.2 × 10−2; combined HR, 1.28; 95% CI: 1.14, 1.43; P=2.2 × 10−5). 

Furthermore, a significant correlation was observed between the variant rs9929218 and a negative response to chemotherapy (P=3.9 x 10-4).

The study suggests that these findings provide a mechanism underlying rs9929218’s potential in making a patient prognosis.

Four regions in the human genome linked to pancreatic cancer risk have been identified.
Patients with colorectal cancer who have the variant rs9929218 at 16q22 are at an increased risk for worse survival.
Genome-wide association studies have identified numerous loci associated with colorectal cancer risk.
READ FULL ARTICLE From clincancerres.aacrjournals.org

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters